This study examined whether the G-protein polymorphism (GNB3-C825 T) predicts clinical phenotypes in untreated hypertensive subjects. GNB3 genotype had no influence on age at presentation, hypertension severity, arterial stiffness, microalbuminuria or renin-aldosterone axis activation. However, the T allele was associated with significantly lower potassium, higher plasma bicarbonate and higher urinary potassium excretion, with a genedose effect.
The genetic basis of essential hypertension remains poorly understood. A polymorphism in the heterotrimeric G-protein (GNB3-C825 T) gene has shown promise as a potential risk factor for essential hypertension. 1 This polymorphism produces a splice variant of the b-3 subunit, which is associated with alterations in G-protein signaling 2 and activity of the sodium hydrogen exchanger. 3 The T allele has been associated with hypertension in Caucasian populations in a number of large, independent, case-control and cross-sectional studies (odds ratio 1.3-1.8), although with inconsistent results. 1, 4 Recent data suggest that the T allele may be associated with specific phenotypes, such as lowrenin, 5 altered electrolyte homeostasis, 6 obesity, insulin resistance and the metabolic syndrome. 1 The aim of the study was to determine whether the GNB3 polymorphism predicts age of onset, hypertension severity, specific endocrine/biochemical profiles, arterial stiffness and the presence of microalbuminuria. The population consisted of 182 newly diagnosed, never-treated, hypertensive, white Caucasians. The diagnosis of hypertension was based on three blood pressure (BP) measurements X140/90 mm Hg and confirmed by ambulatory monitoring (SpaceLabs, Washington, USA). Subjects with secondary causes of hypertension were excluded. Patients gave informed consent and the study had institutional ethics approval. Patients were studied in the morning after an overnight fast having refrained from caffeine, alcohol and smoking in the previous 12 h, with the patients ambulant and rested in seated position for 10 min. Fasting lipids, glucose, urea and electrolytes were measured by standard methods. Aldosterone and plasma renin activity were measured by radioimmunoassay (Adaltis Italia Inc, Bologna, Italy). Morning urine samples were collected for microalbuminuria and spot urinary sodium and potassium concentrations. The metabolic syndrome was defined using the 2001 ATP III guidelines. 7 Fractional potassium excretion was calculated as (urinary potassium Â plasma creatinine)/(plasma potassium Â urinary creatinine) Â 100. Fractional sodium excretion (FENa) was calculated as (urinary sodium Â plasma creatinine)/(plasma sodium Â urinary creatinine) Â 100. Arterial stiffness (pulse wave velocity (PWV) (Complior) and augmentation index (AIx) (Sphygmocor)) were measured as described previously. 8 Genotyping was performed as described previously. 2 Renin, aldosterone and urinary microalbumin were log-transformed before parametric analysis. Genotype differences were analysed using analysis of variance for continuous variables and w 2 tests for categorical data. The study power, at the 0.05 significance level, to detect a 10 mm Hg difference in BP for the T allele was 0.93; 0.97 for a 1 m/s difference in PWV; 0.99 for a 10% difference in AIx; 0.96 for a 20 mg/l difference in urinary microalbumin; 0.86 for a 150 pmol/l difference in aldosterone and 0.90 to detect a 1.5 ng/ml/h difference in plasma renin activity. Fifty percent were male, with mean age (s.d.) being 48(12) years. Allele frequencies were C:0.61 and T:0.39. Genotype frequencies (CC(37%), CT(48%) and TT(15%)) were consistent with those predicted by Hardy-Weinberg equilibrium. The genotype groups did not differ with regard to mean age, gender or smoking (Table 1) .
There were no genotype differences in BP severity, neither for systolic nor diastolic mean office nor for mean ambulatory BPs (Table 1) . Similarly, genotype influenced neither measure of arterial stiffness nor urinary microalbumin concentration ( Table 1) .
The prevalence of the metabolic syndrome for carriers of the CC genotype was 36%; 46% for CT and 15% for TT (P ¼ 0.02 for TT versus CT/CC). The lower prevalence in TT carriers could be accounted for by smaller waist measurements and lower plasma triglycerides (Table 1) .
Plasma-renin, aldosterone and aldosterone renin ratio (ARR) were similar in all three groups. The T allele was associated with significantly lower plasma potassium levels (P ¼ 0.01), higher plasma bicarbonate (P ¼ 0.02) and higher fractional urinary potassium excretion (P ¼ 0.03) ( Table 1 ) with evidence of a gene-dose effect. Fractional urinary sodium excretion was not influenced by genotype ( Table 1) .
The GNB3 polymorphism has been variously associated with hypertension, 3 low-renin states 5 and components of the metabolic syndrome. 1 In this well-characterised population of newly diagnosed, untreated hypertensive subjects, GNB3 genotype had no influence on age at presentation with hypertension or hypertension severity determined by ambulatory BP monitoring. Similarly, the presence of end-organ damage at disease presentation, as determined by arterial stiffness measurements and the presence of microalbuminuria, did not differ significantly according to genotype.
With the relatively small sample size in this study, it is important to address statistical power. The study was powered to detect clinically meaningful genotype differences, for example a difference of one grade of hypertension according to the WHO/ ISH guidelines, 9 or an increased risk of cardiovascular events in the case of arterial stiffness measurements. 10 Although smaller genotype effects cannot be ruled out, the data suggest that the GNB3 polymorphism does not influence the severity of hypertension or the presence of target organ damage at presentation in a clinically meaningful way.
There was no relationship between GNB3 genotype and renin-aldosterone axis activation. Data on the association between renin status and this polymorphism have been conflicting. 5, 6 There were, however, significant genotype differences in electrolyte homeostasis. Specifically, the T allele was associated with lower potassium levels, higher plasma bicarbonate and higher urinary potassium excretion, with heterozygotes exhibiting levels intermediate between those of CC and TT homozygotes. Martin et al 6 also reported a relationship between the T allele and lower potassium levels. The electrolyte differences are within the normal physiological range, therefore their clinical relevance remains uncertain. The findings raise interesting hypotheses regarding the functional activity of the GNB3 mutation. The higher fractional urinary potassium excretion suggests the polymorphism may modulate potassium and hydrogen ion excretion at a renal level. Interestingly, recent studies have found that subjects with the GNB3 TT polymorphism had a significantly better BP lowering response to diuretic therapy than C allele carriers.
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No relationship was seen with sodium homeostasis. However, subjects were not sodium restricted, therefore, dietary influences could have obscured significant genotype associations. The lower prevalence of the metabolic syndrome for the TT genotype may be a chance finding, as there was no gene-dose effect and the results were contrary to previously published data.
1 Alternatively, the onset of hypertension in TT carriers may be genetically driven and less influenced by environmental factors such as obesity.
In summary, the TT genotype was associated with a biochemical profile characterized by relative hypokalaemia, alkalosis and increased urinary fractional potassium excretion. Additional studies of the biological function of the GNB3 variant in relation to potassium and acid-base homeostasis would be required to fully elucidate the nature of this relationship.
